News & Updates

Show Multimedia Only

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

The novel antisense oligonucleotide bepirovirsen has induced functional cure in one-fifth of patients with chronic hepatitis B virus (HBV) infection in the phase 3 B-Well 1 and B-Well 2 trials.

One in five patients with chronic HBV infection achieves functional cure with bepirovirsen

2 hours ago

$TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients$

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

5 hours ago

Patients with radiographic axial spondyloarthritis (r-axSpA) who have been exposed to tumour necrosis factor inhibitor (TNFi) and interleukin (IL)-17 inhibitor (IL-17i) appear to have a lower risk of osteoporosis, but not hip fracture, than biologic disease-modifying antirheumatic drug (bDMARD)-naïve individuals, a recent study has shown.

TNFi, IL-17i reduce risk of osteoporosis, but not hip fracture, in r-axSpA patients

5 hours ago

LNF-based regimens may alter trajectory of CHD treatment

6 hours ago by

Individuals with chronic hepatitis D (CHD) may benefit from lonafarnib boosted with ritonavir (LNF/RTV) alone or in combination with peg-interferon-alfa (PEG), findings from the phase III D-LIVR trial have shown.

LNF-based regimens may alter trajectory of CHD treatment

6 hours ago

$Lutikizumab shows promise in refractory hidradenitis suppurativa$

Lutikizumab shows promise in refractory hidradenitis suppurativa

10 hours ago

Treatment with lutikizumab appears to improve outcomes in patients with moderate-to-severe hidradenitis suppurativa (HS) who have not responded to anti-TNF therapy, according to a phase II trial.

Lutikizumab shows promise in refractory hidradenitis suppurativa

10 hours ago

Tezepelumab cuts oral corticosteroid use without compromising asthma control

a day ago by

Tezepelumab demonstrates steroid-sparing potential in patients with severe asthma, reducing maintenance oral corticosteroid use while maintaining asthma control, as shown in the phase III SUNRISE study.

Tezepelumab cuts oral corticosteroid use without compromising asthma control

a day ago

Rapid response to obesity medications tied to greater weight loss

a day ago by

A post hoc analysis of the SURMOUNT-5 study reveals more tirzepatide-treated individuals with obesity achieving all body weight (BW) reduction thresholds than semaglutide-treated participants, with rapid responders showing a greater magnitude of weight loss.

Rapid response to obesity medications tied to greater weight loss

a day ago

Daraxonrasib makes history in one of the deadliest cancers

a day ago by

Daraxonrasib—an oral, potent RAS(ON) multi-selective, tri-complex inhibitor—demonstrates unprecedented survival benefits in individuals with previously treated metastatic pancreatic adenocarcinoma (mPDAC) in the landmark phase III RASolute 302 study.

Daraxonrasib makes history in one of the deadliest cancers

a day ago

Oral semaglutide provides limited benefit in individuals with early AD

a day ago

The use of oral semaglutide does not reduce the speed of clinical progression in individuals with early Alzheimer's disease (AD), according to the results to two phase III trials.